Ipsen posts strong growth in 2018 sales and profit

14 February 2019

Shares of French pharma company Ipsen (Euronext: IPN) were up 5.6% at 115.70 euros by 11.18 CET this morning, after the company presented financial results for full-year 2018, showing that group sales grew 16.6% as reported and 20.1% at constant exchange rates to reach 2.22 billion euros ($2.51 billion).

Specialty Care sales grew 24.7% to 1.92 billion euros, reflecting strong performance across all major products and geographies, and Consumer Healthcare revenues grew 2.7% to 300 million euros. Core operating income came in at 659.9 million euros, with growth of 31.0%. Core earnings per share were 5.91 euros, up 35.5%. Core operating margin at 29.7% of net sales was up 3.3 points.

2019 financial guidance

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK